{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T16:55:32Z","timestamp":1782320132018,"version":"3.54.5"},"reference-count":37,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.vaccine.2018.10.086","type":"journal-article","created":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T06:38:49Z","timestamp":1540881529000},"page":"7659-7665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Estimating costs and health outcomes of publicly funded tick-born encephalitis vaccination: A cost-effectiveness analysis"],"prefix":"10.1016","volume":"36","author":[{"given":"Jad","family":"Shedrawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Henriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Pia","family":"Hergens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Helena","family":"Askling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.10.086_b0005","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(08)60800-4","article-title":"Tick-borne encephalitis","volume":"371","author":"Lindquist","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.10.086_b0010","article-title":"Report of the 19th Annual Meeting of the International Scientific Working Group on Tick-Borne Encephalitis (ISW-TBE) \u2013 TBE in a changing world","author":"Kunze","year":"2017","journal-title":"Ticks Tick Borne Dis"},{"key":"10.1016\/j.vaccine.2018.10.086_b0015","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2016.21.39.30355","article-title":"the first tic-borne encephalitis case in the Netherlands: reflections and a note of caution","volume":"21","author":"Clement","year":"2016","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2018.10.086_b0020","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ttbdis.2015.10.013","article-title":"Siberian subtype tick-borne encephalitis virus in Ixodes ricinus in a newly emerged focus, Finland","volume":"7","author":"J\u00e4\u00e4skel\u00e4inen","year":"2016","journal-title":"Ticks Tick Borne Dis"},{"key":"10.1016\/j.vaccine.2018.10.086_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13071-016-1658-3","article-title":"First evidence of established populations of the taiga tick Ixodes persulcatus (Acari: Ixodidae) in Sweden","volume":"9","author":"Jaenson","year":"2016","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.vaccine.2018.10.086_b0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/00365549609027160","article-title":"A 10-year follow-up study of tick-borne encephalitis in the Stockholm area and a review of the literature: need for a vaccination strategy","volume":"28","author":"Haglund","year":"1996","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.086_b0035","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0264-410X(02)00811-3","article-title":"Tick-borne encephalitis - Pathogenesis, clinical course and long-term follow-up","volume":"21","author":"Haglund","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.086_b0040","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1468-1331.2011.03434.x","article-title":"Tick-borne encephalitis in Latvia 1973\u20132009: epidemiology, clinical features and sequelae","volume":"19","author":"Karelis","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.vaccine.2018.10.086_b0045","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1086\/342059","article-title":"Tickborne encephalitis in an area of high endemicity in lithuania: disease severity and long-term prognosis","volume":"35","author":"Mickiene","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.086_b0050","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/ane.12561","article-title":"Tick-Borne Encephalitis sequelae at long-term follow-up: a self-reported case\u2013control study","volume":"134","author":"Veje","year":"2016","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.vaccine.2018.10.086_b0055","article-title":"The long-term outcome of tick-borne encephalitis in Central Europe","author":"Bogovi\u010d","year":"2017","journal-title":"Ticks Tick Borne Dis"},{"key":"10.1016\/j.vaccine.2018.10.086_b0060","first-page":"230","article-title":"Tick-bone encephalitis in Sweden in relation to aseptic meningo-encephalitis of other etiology: a prospective study of clinical course and outcome","volume":"244","author":"G\u00fcnther","year":"1997","journal-title":"J Neurosci"},{"key":"10.1016\/j.vaccine.2018.10.086_b0065","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1016\/j.vaccine.2006.03.061","article-title":"Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN\u00ae: results of two large phase 3 clinical studies","volume":"24","author":"Loew-Baselli","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.086_b0070","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0264-410X(03)00563-2","article-title":"Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicity","volume":"22","author":"Ehrlich","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.086_b0075","unstructured":"World Health Organisation. Vaccines against tick-borne encephalitis: WHO position paper; 2011:241\u201356. http:\/\/doi.org\/10.1186\/1750-9378-2-15.Voir."},{"key":"10.1016\/j.vaccine.2018.10.086_b0080","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3201\/eid1901.120458","article-title":"Vaccination and tick-borne encephalitis, central Europe","volume":"19","author":"Heinz","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.086_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0100860","article-title":"Factors determining immunological response to vaccination against tick-borne encephalitis virus in older individuals","volume":"9","author":"Lindblom","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.10.086_b0090","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.vaccine.2015.12.029","article-title":"Tick-borne encephalitis (TBE) vaccine to medically immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study","volume":"34","author":"Hertzell","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.086_b0095","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1016\/j.vaccine.2010.02.001","article-title":"Vaccine failures after active immunisation against tick-borne encephalitis","volume":"28","author":"Andersson","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.086_b0100","unstructured":"Public Heath Agency of Sweden. Tick Borne Encephalitis (TBE) 2017. https:\/\/www.folkhalsomyndigheten.se\/folkhalsorapportering-statistik\/statistikdatabaser-och-visualisering\/sjukdomsstatistik\/tick-borne-encephalitis-tbe\/."},{"key":"10.1016\/j.vaccine.2018.10.086_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0143875","article-title":"The willingness to pay for vaccination against tick-borne encephalitis and implications for public health policy: evidence from Sweden","volume":"10","author":"Slunge","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.10.086_b0110","unstructured":"Stockholm County Council. TBE-vaccination n.d. http:\/\/www.vardgivarguiden.se\/behandlingsstod\/smittskydd\/amnesomraden\/vaccination\/tbe."},{"key":"10.1016\/j.vaccine.2018.10.086_b0115","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1016\/j.vaccine.2015.07.030","article-title":"Tick borne encephalitis (TBE)-vaccination coverage and analysis of variables associated with vaccination","volume":"33","author":"Askling","year":"2015","journal-title":"Sweden. Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.086_b0120","series-title":"Methods for economic evaluations of health care programmes","author":"Drummond","year":"2005"},{"key":"10.1016\/j.vaccine.2018.10.086_b0125","unstructured":"TLV. L\u00e4kemedelsf\u00f6rm\u00e5nsn\u00e4mndens allm\u00e4nna r\u00e5d 2003:LFNAR 2003:2."},{"key":"10.1016\/j.vaccine.2018.10.086_b0130","article-title":"Second five-year follow-up after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10 years antibody persistence","author":"Beran","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.086_b0135","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1016\/j.vaccine.2017.03.059","article-title":"Seropersistence of TBE virus antibodies 10 years after first booster vaccination and response to a second booster vaccination with FSME-IMMUN 0.5 mL in adults","volume":"35","author":"Konior","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.086_b0140","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1586\/14760584.5.4.461","article-title":"Are tick-borne encephalitis vaccines interchangeable?","volume":"5","author":"Br\u00f6ker","year":"2006","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.10.086_b0145","unstructured":"Statistics Sweden. D\u00f6dstal per 1000 av medelfolkm\u00e4ngden efter \u00e5lder och k\u00f6n. \u00c5r 2000 - 2016 2017. http:\/\/www.statistikdatabasen.scb.se\/pxweb\/sv\/ssd\/START__BE__BE0101__BE0101I\/Dodstal\/?rxid=9e791d4b-2907-44cc-b19b-e720f5de8850."},{"key":"10.1016\/j.vaccine.2018.10.086_b0150","doi-asserted-by":"crossref","unstructured":"Stockholm County Council. Vaccines price list 2017:2017.","DOI":"10.12968\/cypn.2017.11.51"},{"key":"10.1016\/j.vaccine.2018.10.086_b0155","unstructured":"Stockholm County Council. VAL database. Stockholm: 2014."},{"key":"10.1016\/j.vaccine.2018.10.086_b0160","unstructured":"Ghatnekar O, Steen Carlsson K. cost of illness of Stroke 2009. Stockholm: 2012."},{"key":"10.1016\/j.vaccine.2018.10.086_b0165","unstructured":"Stockholm County Council. folkh\u00e4lsorapport. Stockholm: 2015."},{"key":"10.1016\/j.vaccine.2018.10.086_b0170","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/2396987316683780","article-title":"Dependency and health utilities in stroke: data to inform cost-effectiveness analyses","volume":"2","author":"Ali","year":"2017","journal-title":"Eur Stroke J"},{"key":"10.1016\/j.vaccine.2018.10.086_b0175","series-title":"Decision modelling for health economic evaluation","author":"Briggs","year":"2006"},{"key":"10.1016\/j.vaccine.2018.10.086_b0180","article-title":"H\u00e4lsoekonomisk analys av allm\u00e4n TBE-vaccinering av inv\u00e5narna i","author":"S\u00f6rmland","year":"2013","journal-title":"S\u00f6rmland"},{"key":"10.1016\/j.vaccine.2018.10.086_b0185","doi-asserted-by":"crossref","first-page":"6301","DOI":"10.1016\/j.vaccine.2012.07.083","article-title":"Cost-effectiveness of tick-borne encephalitis vaccination in Slovenian adults","volume":"30","author":"\u0160mit","year":"2012","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18314737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18314737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T14:26:01Z","timestamp":1694010361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18314737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":37,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0264410X18314737"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.10.086","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimating costs and health outcomes of publicly funded tick-born encephalitis vaccination: A cost-effectiveness analysis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.10.086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}